Granules India secures first-to-file ANDA for Sodium Oxybate

6 Jul 2026via NSE FilingSource

English हिंदी తెలుగు தமிழ்ಕನ್ನಡ मराठी বাংলা ગુજરાતી

Granules India secures first-to-file ANDA for Sodium Oxybate Extended-Release for Oral Suspension. This milestone could lead to 180-day marketing exclusivity upon FDA approval. The drug has a US market size of $400 million annually. Approval may boost revenues significantly in the coming years.

📊 STOCKS: GRANULES | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma

#Pharma#FDA#ANDA

Stocks mentioned

GRANULESGRANULES

⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.

Trade smarter on NSE

Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.

Start for ₹1 →